1. Show article details.

    BRIEF-Resmed Entered Into A Certain Second Amended And Restated Credit Agreement

    Reuters – 6:12 PM ET 06/30/2022

    Resmed Inc (RMD): * RESMED (RMD)- ON JUNE 29 CO ENTERED INTO A CERTAIN SECOND AMENDED AND RESTATED CREDIT AGREEMENT. * Resmed Inc (RMD)- REVOLVING CREDIT AGREEMENT PROVIDES CO REVOLVING CREDIT FACILITY IN AN AGGREGATE AMOUNT OF $1.5 BILLION. * Resmed Inc (RMD)- REVOLVING CREDIT AGREEMENT TERMINATES ON JUNE 29, 2027.

  2. Show article details.

    ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care

    GlobeNewswire – 9:00 AM ET 06/28/2022

    SAN DIEGO, June 28, 2022 -- ResMed (RMD) today announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022. Blaise, currently ResMedÂ’s Vice President of Sleep & Respiratory Care for Western Europe, is a medtech industry thought leader with over 25 yearsÂ’ experience in medical device sales, marketing, finance, and business development.

  3. Show article details.

    Analyzing ResMed's Short Interest

    Benzinga – 1:03 PM ET 06/22/2022

    ResMed's short percent of float has risen 5.62% since its last report. Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock.

  4. Show article details.

    Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years

    Benzinga – 4:49 PM ET 06/15/2022

    ResMed has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81 billion. Buying $1000 In RMD: If an investor had bought $1000 of RMD stock 15 years ago, it would be worth $9,426.23 today based on a price of $203.79 for RMD at the time of writing.

  5. Show article details.

    US STOCKS-Wall Street set to rebound after Monday's rout

    Reuters – 9:19 AM ET 06/14/2022

    * Futures up: Dow 0.39%, S&P 0.59%, Nasdaq 0.91% * Oracle rises as sales, profit top estimates on cloud boom. * Continental Resources (CLR) jumps on buyout proposal from founder. By Anisha Sircar.

  6. Show article details.

    ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How

    Benzinga – 7:44 AM ET 06/14/2022

    ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How

  7. Show article details.

    US STOCKS-Futures edge higher after Monday's rout on Wall Street

    Reuters – 7:22 AM ET 06/14/2022

    * Futures up: Dow 0.34%, S&P 0.54%, Nasdaq 0.87% U.S. stock index futures pointed to a potential rebound on Wall Street on Tuesday after a sharp selloff in the previous session pushed the S&P 500 into bear market territory.

  8. Show article details.

    Deals of the day-Mergers and acquisitions

    Reuters – 5:57 AM ET 06/14/2022

    The following bids, mergers, ** Medical equipment maker ResMed Inc (RMD) said it will buy German healthcare software provider MEDIFOX DAN GmbH in a $1 billion deal to expand in software-as-a-service outside the United States.

  9. Show article details.

    Medical device maker ResMed to acquire Germany's MEDIFOX DAN in $1 bln deal

    Reuters – 3:09 AM ET 06/14/2022

    Medical equipment maker ResMed Inc (RMD) said on Tuesday it will buy German healthcare software provider MEDIFOX DAN GmbH in a $1 billion deal to expand in software-as-a-service outside the United States. MEDIFOX, owned by private-equity firm Hg, is a provider of software to more than 6,000 ambulatory care services, care homes and therapists in Germany, according to the latter's website.

  10. Show article details.

    Resmed to acquire Germany's MEDIFOX DAN for $1 billion

    Reuters – 2:18 AM ET 06/14/2022

    U.S. medical equipment maker Resmed Inc (RMD) said on Tuesday it will acquire German healthcare software provider MEDIFOX DAN for $1 billion.

  11. Show article details.

    BRIEF-ResMed To Acquire MEDIFOX DAN

    Reuters – 2:08 AM ET 06/14/2022

    Resmed Inc (RMD): * RESMED TO ACQUIRE MEDIFOX DAN, A GERMAN LEADER IN OUT-OF-HOSPITAL SOFTWARE SOLUTIONS. * SAYS PURCHASE PRICE OF APPROXIMATELY US$1 BILLION. * UPON CLOSING, ACQUISITION EXPECTED TO BE ACCRETIVE TO RESMED'S NON-GAAP DILUTED EARNINGS PER SHARE. * INTENDS TO RETAIN MEDIFOX DAN'S EMPLOYEES, MANAGEMENT STRUCTURE, LOCATIONS, AND BUSINESS PROCESSES.

  12. Show article details.

    ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions

    GlobeNewswire – 2:05 AM ET 06/14/2022

    SAN DIEGO and HILDESHEIM, Germany, June 14, 2022 -- ResMed (RMD) today announced a definitive agreement to acquire privately held MEDIFOX DAN, a German leader in out-of-hospital software solutions for providers in major settings across the care continuum, from Hg, a leading software and services investor.

  13. Show article details.

    ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference

    GlobeNewswire – 9:00 AM ET 06/07/2022

    ResMed (RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022, beginning at approximately 1:20 p.m. at the Terranea Resort in Rancho Palos Verdes, California.

  14. Show article details.

    Analyst Ratings for ResMed

    Benzinga – 11:22 AM ET 06/06/2022

    Analysts have provided the following ratings for ResMed within the last quarter: According to 4 analyst offering 12-month price targets in the last 3 months, ResMed has an average price target of $258.25 with a high of $280.00 and a low of $233.00. Below is a summary of how these 4 analysts rated ResMed over the past 3 months.

  15. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

    Benzinga – 11:12 AM ET 06/06/2022

    For Ryder System Inc, Wolfe Research upgraded the previous rating of Underperform to Peer Perform. According to B of A Securities, the prior rating for CAE Inc was changed from Underperform to Neutral. For Ardagh Metal Packaging SA, Barclays upgraded the previous rating of Equal-Weight to Overweight. According to Edward Jones, the prior rating for American Express Co was changed from Hold to Buy.

  16. Show article details.

    10 Biggest Price Target Changes For Monday

    Benzinga – 7:45 AM ET 06/06/2022

    Check out this: Insiders Buy Around $10M Of 3 Stocks Don't forget to check out our premarket coverage here .

  17. Show article details.

    A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

    Benzinga – 6:01 AM ET 06/06/2022

    Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May. Futures for the Dow Jones Industrial Average jumped 236 points to 33,124.00 while the Standard & Poor's 500 index futures rose 39.25 points to 4,146.25. Futures for the Nasdaq index climbed 160 points to 12,...

  18. Show article details.

    If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today

    Benzinga – 1:13 PM ET 06/02/2022

    ResMed has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of $30.35 billion. Buying $100 In RMD: If an investor had bought $100 of RMD stock 5 years ago, it would be worth $285.18 today based on a price of $207.47 for RMD at the time of writing.

  19. Show article details.

    ResMed Announces Participation in the 42nd Annual William Blair Growth Stock Conference

    GlobeNewswire – 9:00 AM ET 06/01/2022

    ResMed (RMD) today announced Rob Douglas, president and chief operating officer, will present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022, beginning at approximately 9:20 a.m. at the Loews Chicago Hotel in Chicago.

  20. Show article details.

    ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference

    GlobeNewswire – 9:00 AM ET 05/25/2022

    ResMed (RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisions Conference on Wednesday, June 1, 2022, beginning at approximately 1:30 p.m. at the New York Hilton Midtown in New York City.

Page:

Today's and Upcoming Events

  • Aug
    03

    RMD to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    11

    RMD ex-Dividend for $0.42 on 05/11/2022

    • Announce Date: 04/28/2022
    • Record Date: 05/12/2022
    • Pay Date: 06/16/2022
  • Apr
    28

    RMD announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.